Indian authority withdraws patent for interferon granted to RocheBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e7499 (Published 06 November 2012) Cite this as: BMJ 2012;345:e7499
- Meera Kay
India’s Intellectual Property Appellate Board has repealed the patent granted to the drug company Roche for pegylated interferon alfa-2a (Pegasys), which is used to treat hepatitis C.
The board’s order represents a watershed in the history of patents in India and a victory for patients’ groups fighting to widen access to drugs.
“This is India’s first successful post-grant opposition case,” said Eldred Tellis, director of the Sankalp Rehabilitation Trust, a non-governmental organisation that had challenged the patent. “And it is significant because the patent granted to Roche in 2006 was the first product patent on a medicine in India after …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial